The Evolutionary Stability of Ethics in Pharma Medicine: A Tripartite Replicator Dynamics Approach

Main Contributing & Presenting Author: Alanna Polyak

Project Ideation Support: Brooke H., Denny B., Ekam S., Annika J. | Independent Mathematical Modeling Strictly by Alanna Polyak

Department of Mathematics, Dartmouth College | MATH/QSS 30.04 | Mentor: Professor Thomas Zdyrski

Evolutionary Game Theoretic (EGT) Paradigms

Translating clinical research to the market faces severe economic bottlenecks. While **classical models** assume **high R&D costs drive innovation via patent rewards**, an **evolutionary lens reveals that rigorous "Ethical R&D" is a costly phenotypical trait compared to "Cost-Cutting."** Without exogenous intervention, clinical trial overhead creates evolutionary pressure that **naturally selects for regulatory evasion**. We map this ecosystem using three interacting EGT frameworks:

The Inspection Game (Hawk-Dove Variant): Firms (x) and Regulators (y) exist in an asymmetric predator-prey state. If ethical compliance reaches 100% ($x \rightarrow 1$), regulators retreat ($y \rightarrow 0$) to minimize operational overhead (C_r). This turns compliance into a Sucker's Payoff, incentivizing rapid corporate defection.

Multi-Player Prisoner's Dilemma: As bureaucratic friction (k) scales exponentially, the mathematical "Cost of Ethics" eclipses the "Reward of Approval." Firms must abandon the Pareto Optimal state, forcing a system-wide Nash Equilibrium of Defect-Defect.

Public Goods Game: Public trust (z) is a non-excludable resource. Corrupt cost-cutters act as Free-Riders, draining the reputational capital generated by innovators. Because the public cannot perfectly differentiate between ethical and corrupt firms prior to a clinical failure, the entire industry suffers the resulting stock devaluation.

Mathematical Formulation: Tripartite ODEs

System evolution is governed by the continuous **Replicator Equation**, where variance *x(1-x)* drives selection velocity. We define the coupled Ordinary Differential Equations (ODEs):

$$\frac{dx}{dt} = x(1-x)\left[-(C_{base} + k^3 y) + y\left(S_{pol} + \alpha\right) + z\gamma\right]$$
$$\frac{dy}{dt} = y(1-y)\left[(1-x)B_y - C_r\right]$$
$$\frac{dz}{dt} = z(1-z)\left[(1-x)B_p - C_p\right]$$

- **Populations**: $\in [0,1]$: x (Ethical Firms), y (Regulators), z (Watchful Public)
- **Costs:** C_{base} (Base R&D), C_r (Regulator Overhead), C_p (Public Harm)
- **Incentives/Friction:** k (Bureaucratic Red Tape), S_{pol} (State Subsidy), α (FDA Fine), γ (Public Penalty), B_y, B_p (Institutional Benefits), $k^3 y$ (Non-linear regulatory friction: Eroom's Law)

Core Dynamics & Basins of Attraction

To prove the **stability** of the pharmaceutical ecosystem, we evaluate the system's **Jacobian Matrix** J (representing the first order partial derivatives) at the equilibrium coordinate $E^* = (x^*, y^*, z^*)$

$$J(E^*) = \begin{bmatrix} \frac{\partial \dot{x}}{\partial x} & \frac{\partial \dot{x}}{\partial y} & \frac{\partial \dot{x}}{\partial z} \\ \frac{\partial \dot{y}}{\partial x} & \frac{\partial \dot{y}}{\partial y} & \frac{\partial \dot{y}}{\partial z} \\ \frac{\partial \dot{z}}{\partial x} & \frac{\partial \dot{z}}{\partial y} & \frac{\partial \dot{z}}{\partial z} \end{bmatrix}_{E^*}$$

The system achieves an **Evolutionarily Stable Strategy (ESS) if and only if all eigenvalues (λ_i) of $J(E^*)$ possess strictly negative real parts.** By solving this matrix, we prove that 100% ethical perfection is inherently unstable. The eigenvalues only become strictly negative at an **Interior Mixed ESS**, dictating that a baseline of corruption and oversight must **permanently co-exist.**


Figure 1.1: Global Time Series (Baseline Era)


Figure 1.2: 3D Global Attractor


Figure 1.3: Firms vs Regulators


Figure 1.4: Firms vs Public


Figure 1.5: Regulators vs Public


Figure 2.1: 2D Phase Basin Vector Field


Figure 2.2: 3D Multi-Trajectory Convergence Funnel

Panel I (Core Dynamics): The global time series (1.1) and 3D Attractor (1.2) validate the Jacobian analysis, confirming **convergence to the Interior Mixed ESS.** 1.3 illustrates the **"Inspection Game"**: rising firm compliance prompts regulatory budget cuts, incentivizing opportunistic cheating and creating a spiraling predator-prey dynamic. 1.4 proves **high ethical behavior dampens the market** by suppressing public outrage, while 1.5 shows **institutional dependency**, where intense public scrutiny forces aggressive regulatory enforcement.

Panel II (Basins of Attraction): To assess global resilience, 250 distinct initial state coordinates were simulated. The resulting 2D phase vector field (2.1) and 3D multi-trajectory convergence funnel (2.2) map the topological streamlines. This visualizes an **inescapable global sink**, proving that economic gravity drags the industry into the **identical compliance equilibrium regardless of pristine or corrupt origins.**

Volatility, Time Delays, and Spatial Networks

Standard additive mathematical **models fail in pharmaceuticals because clinical trial failures trigger multiplicative market shocks.** To model this **volatility**, we abandon standard ODEs and evaluate the system using **Geometric Brownian Motion (GBM) via Stochastic Differential Equations (SDEs):**

$$dX_t = \mu(X_t, Y_t, Z_t)dt + \sigma X_t dW_t$$

Here, μ represents our deterministic Replicator drift, σ scales the market volatility, and $dW_t \sim \mathcal{N}(0, dt)$ is a standard Wiener process representing continuous, random clinical outcomes.


Figure 3.1: Geometric Brownian Motion (Clinical Volatility)


Figure 3.2: State Probability Density Function


Figure 3.3: Multiplicative Financial Shock Profile


Figure 3.4: Institutional Hysteresis (Path Dependence)


Figure 3.5: Differential Delay Constraints (FDA Bureaucratic Lag)

The log-normal skew (black swans) in 3.1, has GBM introduce **intense, right-skewed log-normal stock volatility**. However, the Kernel Density Estimate (KDE) in 3.2 verifies that **despite clinical failures**, the **macro-industry** remains probabilistically anchored to the deterministic **ODE ESS**.

3.3 and 3.4 validates the **"Cost of Lost Trust"** as rebuilding a corrupted market requires exponentially greater government subsidies than simply maintaining an already ethical one, resulting in massive economic deadweight loss.

Real-world regulation is not instantaneous; therefore, in 3.5, the FDA's bureaucratic processing lag is modeled using **Time Delay Differential Equations (DDEs):**

$$\frac{dy}{dt} = y(1-y)\left[\left(1 - x(t-\tau)\right)B_y - C_r\right]$$

An FDA audit lag of $\tau = 1.5$ years forces the state to **regulate using outdated historical compliance data.** This delay shifts the Jacobian eigenvalues onto the imaginary axis, inducing Hopf Bifurcations and injecting permanent, **unresolvable systemic oscillation** into the market.

Structural Policy Sensitivity

To quantify structural vulnerabilities of the medical system, a local sensitivity analysis was conducted. The first-order derivative impact of a **$\pm 20\%$ perturbation across all eight parameters** was computed, measuring the delta from the **ESS coordinate to the terminal compliance state.**


Figure 4.1: Evolution under Varying FDA Penalties


Figure 4.2: Evolution under Varying Public Outrage


Figure 4.4: Limit Cycle Constriction via Subsidies


Figure 4.3 Comprehensive 8-Variable Sensitivity Analysis

Varying penalties in 4.1 & 4.2 show that **low baseline fines inherently trap the system in non-compliance.** The ODE trajectories mathematically prove that state fines (α) and public outrage (γ) must cross a critical threshold to flip the expected utility from defection to compliance.

Regulatory asymmetry in 4.3 represent an **adverse 20% increase in Red Tape (k) drops ethical compliance vastly more than an identical 20% decrease improves it.** The mathematical ecosystem is structurally far more vulnerable to bureaucratic friction than it is responsive to exogenous state subsidies. Furthermore, **low baseline fines inherently trap the system in non-compliance**, as corporate actors mathematically rationalize cheating as a **"cost of doing business."**

Limit cycle constriction in 4.4 display that **exogenous state subsidies physically restrict the orbital radius of the market's limit cycles**, imposing a structural financial safety net that dampens catastrophic market oscillation.

Spatial Agglomeration (Cellular Automata)

Continuous ODEs assume infinite, "well-mixed" populations where every firm interacts with every other firm. However, **pharmaceutical competition is strictly localized geographically.** We shatter the well-mixed assumption by deploying a **2D Spatial Cellular Automata (CA).** Firms are mapped onto a topological grid and update their strategies via a **discrete Moore Neighborhood rule:**

$$s_{i,j}^{t+1} = \arg \max_{s \in N(i,j)} (\Pi_s^t)$$


Fig 6.1: Initial State (t=0)


Fig 6.2: Invasion (t=10)


Fig 6.3: Fractal Defense (t=40)


Fig 6.4: Spatial ESS (t=120)


Fig 6.5: Global Spatial Density

The CA matrix mathematically validates **Agglomeration Economics.** As bureaucratic friction (k) increases, isolated ethical firms (blue) undergo rapid extinction. They survive *exclusively* by forming dense, fractal contiguous clusters (e.g., Kendall Square biotech hubs in Boston) to share reputational capital and lock out invading free-riders (red).

Operational Safety Zones (Heatmaps)

To determine the **absolute boundaries of market stability, high-resolution topology** algorithms evaluate the steady-state compliance limit:

$$\lim_{t \to \infty} x(t)$$

We compute this limit across millions of bivariate parameter combinations, mapping the exact algebraic thresholds required to **avert Pitchfork Bifurcations and systemic market collapse.**


Figure 5.1: Subsidy vs Red Tape


Figure 5.2: Subsidy vs Public Outrage


Figure 5.3: Red Tape vs Fines


Figure 5.4: Outrage vs Fines


Figure 5.5: Red Tape vs Base Cost


Figure 5.6: Subsidy vs Regulator Overhead

Subsidy vs. Red Tape & Base Cost: In 5.1 and 5.5, as regulatory complexity (k) scales cubically per Eroom's Law, or as baseline R&D costs (C_{base}) rise, the state must inject **disproportionately massive capital subsidies** just to keep the industry above the 80% safety isoline (dashed line).

Outrage vs. Fines: In 5.4, fines (α) and public penalties (γ) are interchangeable in space; **strong enforcement in one mechanically compensates** for weakness in the other for high compliance.

Friction vs. Fines: In 5.3, extreme bureaucratic friction neutralizes the deterrent effect of FDA fines. If red tape is too high, the market crashes to no compliance regardless of penalty severity.

Subsidy vs. Regulator Overhead: In 5.2 and 5.6, high regulatory costs (C_r) shrink the viable operational window, needing precise subsidy tuning to prevent regulatory bodies from extinction due to little funding.

ML Calibration & Empirical Validation

To **bridge theoretical mathematics with real-world industry behavior**, the parameters θ were dynamically trained against 2010–2024 historical market data. An L-BFGS-B Machine Learning Optimization algorithm was utilized, **computing iterative Jacobians to minimize a weighted Mean Squared Error (MSE) objective function**:

$$\min_{\theta} \mathcal{L}(\theta) = \sum_{t=0}^{14} \omega_t \left[(x_t - \hat{x}_t)^2 + (y_t - \hat{y}_t)^2 + (z_t - \hat{z}_t)^2\right]$$


Figure 7.1: Firm Fit


Figure 7.2: Regulator Fit


Figure 7.3: Public Fit

The calculated validation boxes that display R^2 and MSE prove that the **ML optimized differential equations accurately govern the main behavior of the data of the United States pharmaceutical industry.** Achieving $R^2 > 0.94$ across two of the primary state variables confirms that utilizing the continuous Replicator Dynamics can successfully capture the macro-evolutionary trajectory of the market. The ethical compliance of specific firms is much harder to validate as it varies substantially with the state of the world.

ML Calibration & Empirical Validation Continued


Figure 7.4: Empirical Data Over Optimized Vector Field


Figure 7.6: Bifurcation Crash Overlay (The Paradox Proven)


Figure 7.7: Predictive Market Forecasting (2024-2035)

Vector streamlines in 7.4 show the **theoretical Inspection Game in reality.** The historical industry data (red) aligns with vector streamlines calculated independently by the differential equations.

The paradox proven in 7.6 display the **actual collapse** in empirical market compliance observed between 2020–2024 **breaks cleanly down the identical path predicted** by the theoretical mathematical bifurcation crash line (black). As historical friction (k) crossed the Pitchfork Bifurcation threshold ($k = .88$) the market suffered a deterministic collapse.

Predictive forecasting in 7.7 **extrapolates forward** from 2024 to 2030 reveals that without an immediate, exogenous injection of geometric subsidies to offset current bureaucratic friction, the **pharmaceutical ecosystem will asymptotically approach the zero-compliance boundary.**

3D Topological Manifold & Market Momentum


Figure 8.1: Phase-Space Velocity (The Momentum of Market Collapse)


Figure 8.3: Empirical Correlation Matrix


Figure 8.4: The 3D Topological Manifold of Market Instability

Phase-space velocity in 8.1 computes the **absolute market momentum** (dx/dt). As bureaucratic friction **crossed the critical threshold** around 2020, the velocity that **firms abandoned ethical compliance aggressively and suddenly spiked**, reflecting a flight from a destabilized equilibrium.

The empirical correlation matrix in 8.3 matrix seals the argument, proving an **intensely strong real-world negative correlation** between bureaucratic friction and ethical compliance.

The 3D Topological Manifold in 8.4 defines the absolute geometric boundaries of ethical survival. The cyan line traces the real empirical trajectory. It visualizes that the **market didn't just slowly decline: it was forced off a structural phase-space cliff** generated by unbalanced Red Tape.

Conclusions & Policy Impact

The synthesis of continuous ODEs, log-normal stochastic shocks, and geographic spatial arrays **confirms that ethical clinical trials and companies are an inherently unstable equilibrium.** Punitive regulation alone is fundamentally insufficient to protect patient safety.

This research mathematically proves a counterintuitive **"Regulator-to-Patient" paradox:** increasing the number of regulators actively drives firms toward riskier strategies if the added bureaucracy pushes the operational cost of clinical trials to an unsustainable level.

By quantifying the **bifurcation tipping point**, it shows that subsidies must be continuously and geometrically tuned to perfectly offset Red Tape. **Balancing the evolutionary payoff matrix** is the only way to ensure **ethical safety is the most "fit" survival strategy** in medicine.